Muscle-Specific Tyrosine Kinase and Myasthenia Gravis Owing to Other Antibodies.

Article Details

Citation
Copy to clipboard

Rivner MH, Pasnoor M, Dimachkie MM, Barohn RJ, Mei L

Muscle-Specific Tyrosine Kinase and Myasthenia Gravis Owing to Other Antibodies.

Neurol Clin. 2018 May;36(2):293-310. doi: 10.1016/j.ncl.2018.01.004.

PubMed ID
29655451 [ View in PubMed
]
Abstract

Around 20% of patients with myasthenia gravis are acetylcholine receptor antibody negative; muscle-specific tyrosine kinase antibodies (MuSK) were identified as the cause of myasthenia gravis in 30% to 40% of these cases. Anti MuSK myasthenia gravis is associated with specific clinical phenotypes. One is a bulbar form with fewer ocular symptoms. Others show an isolated head drop or symptoms indistinguishable from acetylcholine receptor-positive myasthenia gravis. These patients usually respond well to immunosuppressive therapy, but not as well to cholinesterase inhibitors. Other antibodies associated with myasthenia gravis, including low-density lipoprotein receptor-related protein 4, are discussed.

DrugBank Data that Cites this Article

Drugs